Stockwatch: Orphans are better, if they work
This article was originally published in Scrip
InterMune’s therapeutic area for many years has been lung diseases and more specifically idiopathic pulmonary fibrosis (IPF). The company's treatment for IPF, pirfenidone, is the only approved drug, and yet it is not available everywhere. The US FDA, for instance, issued a complete response letter in May. Furthermore, InterMune's original intention of partnering its drug has not been realised. What lies behind such regulatory and commercial reticence?
You may also be interested in...
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.